Seattle and South San-Francisco based preclinical biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced Wednesday. The funding will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis and type 1 diabetes. The company’s approach involves engineering a special type of immune cell, a regulatory T cell, to enhance its therapeutic potential. Such cells can quell an overactive immune system, thereby easing symptoms of disease.